Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 363-368

  Sugawara, Kayoko ^a   Inao, Mie ^a   Nakayama, Nobuaki ^a   Mochida, Satoshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

HCV; Pegylated interferon; Retinopathy; Ribavirin; Telaprevir

Indexed keywords

CREATININE; FEBUXOSTAT; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ALLELE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CREATININE BLOOD LEVEL; DETERIORATION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EYE FUNDUS; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINOPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID BLOOD LEVEL; VISUAL ACUITY;

AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RETINAL DISEASES; RIBAVIRIN;

EID: 84896822157     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0889-8     Document Type: Article

References (14)

1. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78-84.
2. Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134-42.
3. Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1-12.
4. Vujosevic S, Tempesta D, Noventa F, et al. Pegylated interferon- associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology. 2012;56:455-63.
5. Okuse C, Yotsuyanagi H, Nagase Y, et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol. 2006;12:3756-9.
6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genet. 2009;41:1105-9.
7. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy: a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139:1190-7.
8. Fujiwara K, Mochida S, Matsuo S, et al. Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol Res. 1998;12:240-51.
9. Fujimori K, Mochida S, Matsui A, et al. Possible mechanisms of elevation of serum transaminase levels during interferon-β therapy in chronic hepatitis C patients. J Gastroenterol. 2002;37:40-6.
10. Mawatari H, Yoneda M, Kirikoshi H, et al. Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2012;47:606-7.
11. Kobayashi T, Hige S, Terashita K, et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol. 2012;47:1228-37.
12. Lotrich FE, Loftis JM, Ferrell RE, et al. IL28B polymorphisms is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interf Cytokine Res. 2011;31:331-6.
13. Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4:e1000017.
14. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory change associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48:368-75.